Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
CA 2225626 C · Owner: Allergan Sales, Inc. · Inventors: Wheeler, Larry A.; Woldemussie, Elizabeth; Lai, Ronald K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method according to which neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula (I) to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death, wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x y and z , may be in any of the remaining 5- 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy is disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 17, 1996 and granted September 3, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 17, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 17, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.